Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

32.29
+0.89002.83%
Post-market: 32.290.00000.00%19:30 EDT
Volume:1.27M
Turnover:41.07M
Market Cap:2.08B
PE:-9.69
High:32.77
Open:31.76
Low:31.52
Close:31.40
52wk High:40.22
52wk Low:18.00
Shares:64.53M
Float Shares:49.01M
Volume Ratio:1.42
T/O Rate:2.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:6.03
PE(LYR):-277.73

Loading ...

U.S. Stocks on the MOVE-Ubiquiti, BJ's Wholesale, Arbutus

Reuters
·
Aug 21

J.P. Morgan Resumes Coverage on Stoke Therapeutics with 'overweight'; Shares Rise

Reuters
·
Aug 21

Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?

Simply Wall St.
·
Aug 19

Stoke Therapeutics Grants New Hires Options for 70,950 Shares at $32.13 Each

Reuters
·
Aug 19

Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report

Simply Wall St.
·
Aug 06

Lexicon Pharmaceuticals Posts Q2 Net Loss

Reuters
·
Aug 06

Stoke Therapeutics CMO Barry Ticho Disposes of USD 208,707 in Common Shares

Reuters
·
Aug 06

Stoke Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Entrada Therapeutics Q2 Net Loss Narrows on Lower Costs

Reuters
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Niagen Bioscience Q2 Net Sales Fall, Missing Estimates

Reuters
·
Aug 05

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)

TIPRANKS
·
Aug 04

Stoke Therapeutics Files for At-the-Market Offering of up to $200 Million in Stock

Reuters
·
Aug 04

Stoke Therapeutics - May Offer up to $200 Mln in Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 04

Stoke Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

Stoke Therapeutics Q2 FY26 Net Loss Widens to $61.62 Million; Revenue Falls to $9.33 Million

Reuters
·
Aug 04

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 04

Stoke Therapeutics Q2 EPS USD -0.93

THOMSON REUTERS
·
Aug 04